Scientific Program


Sunday June 25, 2017

4:00 pm

Registration opens

7.00 pm

Opening Remarks

SESSION 1: Small Molecule Modulators of RNA (Organizer: Amy Ripka)

7.10 pm-7:55 pm

David Chenoweth (University of Pennsylvania)
Modulating Nucleic Acid Structure and Function Using Shape-Selective Small Molecules

8:00 pm-8:45 pm

Nick Murgolo (Merck)
Ribocil - a Selective Antibacterial FMN Riboswitch RNA Inhibitor

8:50 pm-9:35 pm

Hasane Ratni (Roche)
Specific Correction of Alternative Survival Motor Neuron 2 Splicing by Small Molecules: Discovery of a Potential Novel Medicine To Treat Spinal Muscular Atrophy

9:45 pm-11:00 pm




Monday June 26, 2017

8:00 am- 9:00 am

Continental Breakfast

SESSION 2:  Positive Allosteric Modulators (Organizer:  Yves Auberson)

9:00 am-9:45 am

György Miklós Keseru  (Hungarian Academy of Sciences)
Fragment-Based Discovery of Metabotropic Glutamate Receptor 2 (mGluR2)-Positive Allosteric Modulators

9:50 am- 10:35 am

Christa E. Müller  (University of Bonn)
Development of Allosteric Modulators for p2x Receptor Subtypes

10:35 am- 10:55 am


10:55 am- 11:40 am

Douglas Beshore (Merck)
Medicinal Chemistry of M1 Positive Allosteric Modulators for the treatment of Alzheimer’s Disease: Discovery and Development of MK-7622

11:45 am-12:30 pm

Andrew Degnan (Bristol-Myers Squibb)
The Discovery of BMS-955829: Charting the Course to an Efficacious mGluR5 PAM Without Neurotoxicity

12:30 pm

Lunch on your own and free afternoon.

SESSION 3:  Biased Agonism in G Protein-Coupled Receptors (Organizer: Emma Blaney, Chair: Barrie                       Martin)

7:00 pm- 7:45 pm

Philip Pitis (Trevena Pharmaceuticals)
Oliceridine (TRV130) - From Concept to Clinic

7:50 pm- 8:35 pm

Robert Glen (University of Cambridge)
Receptor Bias at the Apelin Receptor: From Design to First In-Man Studies

8:40 pm- 9:25 pm

Jing Liu (Mount Sinai Research)
Discovery of β-arrestin- and Gi-biased Agonists of Dopamine D2 Receptors

9:30 pm- 11:00 pm



Tuesday June 27, 2017

8:00 am- 9:00 am

Continental Breakfast

SESSION 4   Targeting Regulated Cell Death in Drug Discovery (Organizer: Koen Augustyns)

9:00 am- 9:45 am

Peter Vandenabeele (Ghent University)
"Necrotic Cell Death, from Molecular Mechanisms to Experimental Therapy in Inflammatory Diseases"

9:50 am-10:35 am

Andreas Linkermann (Universitätlinikum Carl Gustav Carus)
Ferroptosis and Necroptosis as Therapeutic Targets

10:35 am- 10:55 am


10:55 am-11:40 am

Phillip Harris (GlaxoSmithKline USA)
Identification of a First-in-Class RIP1 Kinase Inhibitor in Phase 2A Trials for Immuno-inflammatory Diseases

11:45 am-12:30 am

Snahel Patel (Genentech)
Discovery of Potent and Selective Inhibitors of Receptor-Interacting Protein Kinase 1 (RIPK1) with In-vivo Activity

12:45 pm

Group Lunch

SESSION 5 Drug Discovery in Academia (Organizer: John Macor)

2:00 pm-2:45 pm

Michael Jung    (University of California at Los Angeles)
Drug Discovery in Academia: Some Success Stories

2:50 pm-3:35 pm

Barry Potter (Oxford University)
Sulfatase Inhibition from Concept to Clinic and Beyond

3:40 pm-4:25 pm

Craig Crews (Yale University)
PROTACs: Controlled Proteostasis as a Therapeutic Strategy

6:30 pm

Symposium Banquet


Wednesday June 28, 2017

8:00 am- 9:00 am

Continental Breakfast

SESSION 6   Latest in Antiviral Research (Organizer: Jeff Zablocki)

9:00 am- 9:45 am

Dustin Siegel (Gilead)
Discovery of a Novel Nucleotide Prodrug GS-5734 for the Treatment of Ebola Virus Disease and Emerging Viruses

9:50 am-10:35 am

Michael Sofia (Arbutus)
Hepatitis B: Is There a Path to a Cure?

10:40 am-11:25 am

Koen Vandyck (Johnson and Johnson)
Capsid Assembly Modulators Against Chronic Hepatitis B Virus Infection

11:30 am

Lunch on your own.

SESSION 7  Latest in Immunooncology and Epigenetics in Treating Cancer  (Organizer: Lori Gavrin)

1:30 pm-2:15 pm

Dai-Shi Su (GlaxoSmithKline USA)
Medicinal Chemistry Enabling SMYD3 Target (In)Validation

2:20 pm-3:05 pm

Emily Cherney  (Bristol-Myers Squibb)
IDO inhibitors for the Treatment of Cancer

3:10 pm-3:55 pm

Eddy Yue (Incyte)
INCB24360 (epacadostat), an IDO Inhibitor for Immunooncology

4:00 pm

Closing remarks